By Adriano Marchese


AstraZeneca PLC said Friday that initial Covid-19 vaccine volumes in Europe will be lower than anticipated in January.

"While there is no scheduled delay to the start of shipments of our vaccine should we receive approval in Europe, initial volumes will be lower than originally anticipated," a spokesperson for the pharmaceutical company said.

AstraZeneca blamed the lower volumes on reduced yields at a manufacturing site within its European supply chain.

"We will be supplying tens of millions of doses in February and March to the European Union, as we continue to ramp up production volumes," the spokesperson added.


Write to Adriano Marchese at


(END) Dow Jones Newswires

January 22, 2021 13:54 ET (18:54 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.